98 related articles for article (PubMed ID: 9147713)
1. Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations.
Jaehde U
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):76-8. PubMed ID: 9147713
[No Abstract] [Full Text] [Related]
2. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Moeung S; Chevreau C; Marsili S; Massart C; Fléchon A; Delva R; Gravis G; Lotz JP; Bay JO; Gross-Goupil M; Filleron T; Delmas C; Lafont T; Chatelut E; Thomas F
Pharm Res; 2020 Jul; 37(7):147. PubMed ID: 32676789
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
7. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Thomas HD; Porter DJ; Bartelink I; Nobbs JR; Cole M; Elliott S; Newell DR; Calvert AH; Highley M; Boddy AV
Br J Clin Pharmacol; 2002 Jan; 53(1):83-91. PubMed ID: 11849199
[TBL] [Abstract][Full Text] [Related]
8. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
[TBL] [Abstract][Full Text] [Related]
11. [Bayesian estimation of pharmacokinetic parameters of etoposide].
Evene E; Chatelut E; Tranchand B; Canal P; Lochon I; Iliadis A; Ardiet CJ
Bull Cancer; 1997 Jul; 84(7):699-703. PubMed ID: 9339195
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
Olver I; Keefe D; Myers M
Intern Med J; 2005 Jul; 35(7):405-8. PubMed ID: 15958110
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for good-risk germ-cell tumors.
Ryan CJ; Bajorin DF
Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
15. Intraocular concentrations of chemotherapeutic agents after systemic or local administration.
Mendelsohn ME; Abramson DH; Madden T; Tong W; Tran HT; Dunkel IJ
Arch Ophthalmol; 1998 Sep; 116(9):1209-12. PubMed ID: 9747681
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.
Fleischhack G; Reif S; Hasan C; Jaehde U; Hettmer S; Bode U
Br J Cancer; 2001 Jun; 84(11):1453-9. PubMed ID: 11384092
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetically guided administration of chemotherapeutic agents.
van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
[TBL] [Abstract][Full Text] [Related]
18. Re: 'A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: a randomized trial'.
Bregni M; Pedrazzoli P
J Natl Cancer Inst; 2009 Jan; 101(1):67; author reply 67-8. PubMed ID: 19116385
[No Abstract] [Full Text] [Related]
19. Level of evidence for therapeutic drug monitoring for etoposide after oral administration.
Gerritsen-van Schieveen P; Royer B;
Fundam Clin Pharmacol; 2011 Jun; 25(3):277-82. PubMed ID: 20608987
[TBL] [Abstract][Full Text] [Related]
20. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
Li X; Choi JS
Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
